Search results
Showing 211 to 225 of 672 results for diabetes
Healthy.io test for home testing of urine albumin to creatinine ratio (MIB221)
NICE has developed a medtech innovation briefing (MIB) on Healthy.io test for home testing of urine albumin to creatinine ratio .
This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186
This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.
Dexcom G6 for real-time continuous glucose monitoring (MIB233)
NICE has developed a medtech innovation briefing (MIB) on Dexcom G6 for real-time continuous glucose monitoring .
with diabetes to achieve blood glucose targets before pregnancy? Any explanatory notes(if applicable) Babies born to women with...
Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) for treating acute coronary syndromes in adults.
optimal frequency for self‑monitoring of blood glucose in adults with type 2 diabetes? Any explanatory notes(if applicable) Why this is...
Diabetes: blood pressure (without moderate or severe frailty)
This indicator has been updated and replaced by NICE indicator 249.
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]
Awaiting development Reference number: GID-TA11700 Expected publication date: TBC
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [TSID11888]
Awaiting development Reference number: GID-TA11377 Expected publication date: TBC
Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.
Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.
Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.
This quality standard covers clinical assessment, prioritising and managing healthcare for adults aged 18 years and over with 2 or more long-term health conditions (multimorbidity). At least 1 of these conditions must be a physical health condition. It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
View recommendations for TA223Show all sections